Vanguard Group’s Petros Pharmaceuticals PTPI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,272
| Closed | -$2.19K | – | 4317 |
|
|
2025
Q1 | $2.19K | Hold |
1,272
| – | – | ﹤0.01% | 4279 |
|
|
2024
Q4 | $12.5K | Hold |
1,272
| – | – | ﹤0.01% | 4279 |
|
|
2024
Q3 | $11.4K | Hold |
1,272
| – | – | ﹤0.01% | 4321 |
|
|
2024
Q2 | $14.6K | Hold |
1,272
| – | – | ﹤0.01% | 4375 |
|
|
2024
Q1 | $47.1K | Hold |
1,272
| – | – | ﹤0.01% | 4323 |
|
|
2023
Q4 | $44.9K | Hold |
1,272
| – | – | ﹤0.01% | 4381 |
|
|
2023
Q3 | $55K | Hold |
1,272
| – | – | ﹤0.01% | 4400 |
|
|
2023
Q2 | $64.6K | Buy |
1,272
+836
| +192% | +$65.1K | ﹤0.01% | 4431 |
|
|
2023
Q1 | $15.2K | Sell |
436
-356
| -45% | -$20.3K | ﹤0.01% | 4538 |
|
|
2022
Q4 | $46.1K | Sell |
792
-232
| -23% | -$22.4K | ﹤0.01% | 4452 |
|
|
2022
Q3 | $131K | Buy |
1,024
+547
| +115% | +$99.3K | ﹤0.01% | 4470 |
|
|
2022
Q2 | $100K | Buy |
477
+22
| +5% | +$5.51K | ﹤0.01% | 4549 |
|
|
2022
Q1 | $178K | Sell |
455
-150
| -25% | -$63.2K | ﹤0.01% | 4551 |
|
|
2021
Q4 | $504K | Buy |
605
+166
| +38% | +$97.2K | ﹤0.01% | 4432 |
|
|
2021
Q3 | $219K | Buy |
439
+9
| +2% | +$5.85K | ﹤0.01% | 4479 |
|
|
2021
Q2 | $336K | Buy |
430
+75
| +21% | +$60K | ﹤0.01% | 4322 |
|
|
2021
Q1 | $331K | Buy |
355
+107
| +43% | +$101K | ﹤0.01% | 4198 |
|
|
2020
Q4 | $273K | Buy |
+248
| New | +$233K | ﹤0.01% | 4054 |
|
Vanguard Group's PTPI Position: Q2 2025 in Review
Vanguard Group sold out of Petros Pharmaceuticals (PTPI) in Q2 2025, closing a stake of 1,272 shares — an estimated $2.19K sold.
Vanguard Group first reported a position in PTPI in Q4 2020 and held it in 18 quarters. The position peaked at $504K in Q4 2021. 0 funds tracked by Wall St. Rank hold PTPI as of Q2 2025.
- Vanguard Group reported no remaining Petros Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Vanguard Group sold 1,272 Petros Pharmaceuticals shares in Q2 2025, an estimated $2.19K.
- Vanguard Group first reported a position in Petros Pharmaceuticals in Q4 2020 and held it in 18 quarters.
- Vanguard Group's Petros Pharmaceuticals position peaked at $504K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q2 2025.
Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.